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Abstract
Background: Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee
osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of
subchondral bone marrow lesions (BMLs) over 6 months in knee OA patients with significant knee pain and BMLs.
A longer, larger study is required to assess whether decreases in BML size will translate to reductions in cartilage
loss over time. We are currently conducting a multicentre, randomised, double-blind, placebo-controlled trial over
24 months that aims to compare the effect of annual infusions of zoledronic acid to placebo on knee structural
change (assessed using magnetic resonance imaging (MRI)) and knee pain in knee OA patients.
Methods: Two hundred sixty-four patients with clinical knee OA, significant knee pain and subchondral BMLs
present on MRI will be recruited in Hobart, Melbourne, Sydney and Adelaide. They will be randomly allocated to
the two arms of the study, receiving an annual identical intravenous infusion of either 100 mL of fluid containing
zoledronic acid (5 mg/100 mL) or placebo (0.9% NaCl 100 mL), at baseline and 1 year later. MRI of the study knee
will be performed at screening, month 6 and 24. Knee structure, symptoms and function will be assessed using
validated methods. The primary outcome is absolute change in tibiofemoral cartilage volume (mm3) over 24 months.
Secondary outcomes include improvement in knee pain over 3, 6, 12, 18, and 24 months and reductions in BML size
over 6 and 24 months. The primary analyses will be intention-to-treat analyses of primary and secondary outcomes. Per
protocol analyses will be performed as the secondary analyses.
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Discussion: This study will provide high-quality evidence to assess whether zoledronic acid has a novel disease modifying
effect in OA by slowing cartilage loss and reducing pain. If zoledronic acid proves effective, it suggests great potential for
cost savings through a delay or reduced need for joint replacement surgery, and potential for great improvements in
quality of life for OA suffers.
Trial registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000039785, registered on 14 January 2013.
Keywords: Zoledronic acid, Osteoarthritis, Cartilage, Pain, Magnetic resonance imaging (MRI)
Background
Osteoarthritis (OA) is a major cause of pain, functional
limitations and disability worldwide [1], with hip and
knee OA ranked as the 11th highest contributor to glo-
bal disability and 38th highest in disability-adjusted life
years (DALYs) [2]. Current therapies focus on alleviating
pain but pain control remains poor in 50% of patients
[3]. Furthermore, despite the large disease burden OA
has, there are currently no approved disease-modifying
OA drugs (DMOADs) that can prevent or stop the joint
damage that the disease causes. Therefore, there is a
major need to develop new, effective therapies.
The overall lack of treatment efficacy for OA may be
partly due to treating everyone as if they have the same
pathological process. OA is a complex, heterogeneous
disease with multiple phenotypes [4, 5]. Treatment can
be optimised by selecting study populations by sub-
groups with specific features that are likely to respond to
particular treatments. One such phenotype is a “bone–
specific phenotype” [6].
Subchondral bone marrow lesions (BMLs), visible on
magnetic resonance imaging (MRI) have been shown to
be an important feature in OA. On MRI they appear as
regions of increased signal intensity within the bone
marrow, and are a promising target for therapy. In ani-
mal models they are the first sign of OA after experi-
mental ligament damage and precede cartilage erosion
and degeneration [7]. In humans they are strongly
correlated with knee pain [8–10]. Both incident [8] and
progressing [10, 11] BMLs are associated with the devel-
opment of knee pain. Further, a reduction in BML size is
associated with pain improvement [11]. Importantly,
BMLs are also associated with structural changes. They
predict site-specific joint space narrowing (JSN) in those
with symptomatic knee OA [12], progression of cartilage
defects [13, 14] and cartilage loss on MRI [14–17].
BMLs also predict total knee replacement over periods
of up to 4 years [11, 18–22]. In some studies, BMLs pre-
dict knee replacements more strongly than other predic-
tors assessed in the same cohort [18, 21].
Bisphosphonates are a class of drugs that slow bone loss
and are commonly used to treat osteoporosis. Bispho-
sphonates are a potential candidate for treating bony
phenotypes of OA. In animal studies, bisphosphonates
(alendronate, tiludronate) improve OA-related progres-
sion of structural damage [23–25]. In humans, data from
general practice datasets demonstrate that bisphosphonate
use (including ibandronate, pamidronate, risedronate,
zoledronate) reduces risk of incident knee replacement in
older women by 26% [26]. However, efficacy of bispho-
sphonates remains complex [27] and therefore effects on
OA outcomes may differ by bisphosphonate type. While
the effect of bisphosphonates on OA outcomes could be a
class effect, bisphosphonates given intravenously appear
to have greater treatment effects, at least, for osteoporosis
[28]. A recent meta-analysis [29] of randomised controlled
trials (RCTs) concluded that bisphosphonates were inef-
fective for reducing symptoms and radiographic progres-
sion in knee OA, but the studies included were dominated
by trials of risedronate (92% of included patients received
oral risedronate) [30, 31]. The authors went on to high-
light that bisphosphonates may be beneficial in certain
patients subgroups (e.g. patients who display high rates of
subchondral turnover) [29]. Trials testing risedronate for
knee OA have demonstrated reduced markers of cartilage
degradation and bone resorption, but no differences in pain,
radiographic joint space width (JSW), or osteophyte forma-
tion over 12–24 months compared to placebo [30, 31].
Alendronate was the most commonly used bisphos-
phonate in the Osteoarthritis Initiative (OAI) (> 60%)
[32]. Indeed, women using bisphosphonates (i.e. alendro-
nate) experienced reduced knee pain in the first 3 years
of observation. There was a trend to less JSN in bisphos-
phonate users over time (year 4, 0.51 vs 0.29 mm; p =
0.06). There was no difference in risk of knee replace-
ment, but the study was underpowered to assess this
outcome. However, in another study, alendronate use
had no effect on Western Ontario and McMasters Uni-
versities Osteoarthritis Index (WOMAC) outcomes after
6 months, and this study did not assess any structural
outcomes [33]. Data from the Fracture Intervention
Trial showed that alendronate retarded spinal osteophyte
progression and disc space narrowing, suggesting that
alendronate may have a structural effect on pathological
processes in spinal OA [34].
Intra-articular (IA) clodronate (versus hyaluronic acid)
was ineffective for knee pain in patients with knee OA
over 5 weeks [35], but intravenous (IV) clodronate was
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effective for reducing pain in erosive hand OA (versus
hydroxychloroquine) at 3 months in a 24-month open
randomised pilot trial [36].
Bisphosphonates may work in OA primarily through
their effects in the subchondal bone. BMLs identify re-
gions of increased subchondral turnover and therefore an
OA biomarker that can predict response to bisphospho-
nates. The earliest evidence for effects of bisphosphonates
on BMLs comes from observational data showing that
BMLs are less common in persons taking alendronate
[37]. Risedronate (50 mg weekly) prevented an increase in
BML size over 24 months [38], although this did not reach
statistical significance. In a different analysis of data from
the OAI, there was a trend (p = 0.07) towards having
decreased BMLs after 12 months, in women who com-
menced an oral bisphosphonate (alendronate or risedro-
nate) [39], compared to matched controls; although the
size of BMLs was similar after 12 months of observation.
In our randomised, double-blind, placebo-controlled pilot
trial, we demonstrated that zoledronic acid (an extremely
potent bisphosphonate) reduced knee pain and size of
BMLs, and increased the proportion of patients improving
over 6 months [40]. Therefore, more potent antiresorp-
tives such as zoledronic acid may be efficacious for treat-
ing pain and resolving BMLs in people with OA. Based on
these findings a longer, larger study is required to assess
whether the decreases in BML size relating to zoledronic
acid treatment will translate to reductions in cartilage loss
over time. This can be hypothesised from observational
studies showing both presence and severity of BMLs pre-
dict cartilage loss [14–17].
Objective
We are conducting a multicentre, randomised, double-
blind, placebo-controlled trial over 24 months to compare
the effect of annual infusions of zoledronic acid to placebo
on knee structural change (assessed using MRI) and knee
pain in 264 patients with clinical knee OA, significant
knee pain and subchondral BMLs. We hypothesise that
zoledronic acid will reduce the loss of knee cartilage vol-
ume over 24 months (primary hypothesis), improve knee
pain over 3, 6, 12, 18, and 24 months (secondary hypoth-
esis) and reduce BML size over 6 and 24 months (second-
ary hypothesis) compared with placebo. If zoledronic acid
proves effective, it will offer a novel therapeutic approach
to reduce knee OA progression.
Methods
Study design
The Zoledronic Acid for Osteoarthritis Knee Pain (ZAP2)
study is a multicentre, randomised, double-blind, placebo-
controlled trial over 24 months. The trial was registered
on the Australian New Zealand Clinical Trials Registry
prior to recruitment, and trial reporting will be guided by
the Consolidated Standards of Reporting Trials (CON-
SORT) Statement [41]. We aim to recruit a total of 264
patients with clinical knee OA, significant knee pain and
subchondral BMLs present on MRI. Patients will be
recruited via the OA Clinical Trial Network in Hobart,
Melbourne, Sydney and Adelaide, using a combined strat-
egy, including collaboration with general practitioners,
rheumatologists, and orthopaedic surgeons, as well as
advertising through local and social media. Patients will
be encouraged to contact their local research nurse via
email or telephone. Each site aims to recruit 66 patients.
Ethics approval has been obtained from the Tasmania
Health and Medical Human Research Ethics Committee
(H0012941), The Alfred Hospital Ethics Committee (03/
13), Monash University Human Research Ethics Commit-
tee (CF14/1064–2,014,000,452), Northern Sydney Local
Health District Ethics Committee (HREC/13/HAWKE/80)
and Human Research Ethics Committee (TQEH/LMH/
MH) (HREC/13/TQEHLMH/134). Written informed con-
sent will be obtained from all patients by the study doctor
(i.e. a rheumatologist or supervised rheumatology advanced
registrar).
Inclusion criteria
The inclusion criteria are as follows: males and females
with significant knee pain on most days (defined as a
pain score ≥ 40 mm on a 100-mm visual analogue scale
(VAS)); aged ≥50 years old; with a subchondral BML
present on MRI; and meeting the American College of
Rheumatology (ACR) criteria for symptomatic knee OA
[42], assessed by a rheumatologist.
Exclusion criteria
The exclusion criteria were as follows:
1) Prior use of bisphosphonates, except according to
the washout schedule:
2 years (if use > 48 weeks).
1 year (if used > 8 weeks but < 48 weeks).
6 months (if used > 2 weeks but < 8 weeks).
2 months (if used < 2 weeks).
Any intravenous bisphosphonate within the prior
2 years.
2) History of non-traumatic iritis or uveitis.
3) Abnormal blood tests [serum calcium > 2.75 mmol/
L (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL) or
creatinine clearance < 35 ml/min].
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4) Serum 25-hydroxyvitamin D concentrations <
40 nmol/L. Patients with serum 25-hydroxyvitamin D
concentrations < 40 nmol/L will have the option to
be prescribed vitamin D supplementation and can
enter the trial once their serum 25-hydroxyvitamin D
concentration level is ≥40 nmol/L.
5) Use of any investigational drug(s) and/or devices
within 30 days or 5 half-lives (whichever is longer)
of the drug prior to randomisation.
6) Prior diagnosis of cancer (metastatic cancer or
cancer diagnosed < 2 years ago where treatment is
still ongoing).
7) Poor dental fitness: A dental exam with appropriate
preventative dentistry will be considered prior to
treatment with bisphosphonates in patients with
concomitant risk factors (e.g. cancer, chemotherapy,
corticosteroids, poor hygiene).
8) Severe knee OA (JSN on X-ray of Grade 3 using
the Osteoarthritis Research Society International
(OARSI) atlas [43]).
9) Other forms of arthritis in which disease is active and
concomitant medication is used (e.g. rheumatoid
arthritis or other inflammatory arthritis).
10) Patients who have undergone arthroscopy or open
surgery in the index knee in the last 12 months.
11)Women who are pregnant or breast feeding.
12) Patients who have had a corticosteroid injection in
the last 3 months or a hyaluronic acid injection in
the last 6 months in the index knee.
13) Planned joint replacement surgery.
14) Contraindication to MRI scanning (for example,
implanted pacemaker, metal sutures, presence of
shrapnel or iron filings in the eye, claustrophobia,
knee too large for coil).
15) Inability to give informed consent.
Randomisation and blinding
Allocation of patients in a 1:1 ratio to either the active
or placebo group will be based on computer generated
random numbers using a central randomisation website
hosted by the University of Tasmania. Block randomisa-
tion, using a block size of 10 (5 in each arm) will be
used. This means that of every 10 patients randomised,
5 will receive active and 5 placebo. The randomisation
will be stratified by study site. This will be conducted by
a staff member at each study site with no direct involve-
ment in the study.
The randomised controlled trial will be a double-blind
one, with both patients and investigators assessing out-
comes blinded to treatment allocation. Allocation con-
cealment and double blinding will be ensured by 1) the
use of identical IV infusions for each group; 2) objective
measures of knee structural changes being made by
trained observers blinded to group allocation; and 3)
subjective measures being taken by research nurses
blinded to group allocation.
Emergency unblinding will be allowed in limited situa-
tions that impact on the safety of study patients.
Code-break for the full randomisation schedule will be
maintained by the University of Tasmania. Patients who
are unblinded will be withdrawn from treatment but will
continue to be followed as per the planned follow-up
schedule.
Intervention
All patients will continue usual care by their treating
health practitioners. Eligible patients will receive an
annual identical intravenous infusion of either 100 mL of
fluid containing zoledronic acid (5 mg/100 mL) or placebo
(0.9% NaCl 100 mL), at baseline and 1 year later.
VOLT01 sub-study
During this trial, an industry funded sub-study will be
added to the Hobart site. Zoledronic acid infusions are
often accompanied by the side effects of acute phase
reactions. This is characterised by flushing, fever, joint
pains, and muscle aches in the period of time just after
infusion (around 3 days post-infusion), and affects
approximately 30% of patients [44]. The VOLT01
sub-study aims to examine whether adding 10 mg of
methylprednisolone immediately following a zoledronic
acid infusion can reduce the rate of acute phase reactions.
Therefore, approximately half way through the trial the
randomisation schedule will change at the Hobart site
only, where patients will be randomised to one of three
identical treatments: zoledronic acid, zoledronic acid
PLUS methylprednisolone (VOLT01), or placebo. The
details of this sub-study will be written up in a separate
paper. We do not foresee that this sub-study will influence
the integrity of this larger trial, which will only analyse
data from patients randomised to zoledronic acid or pla-
cebo. The study rheumatologist at the Hobart site will ob-
tain informed consent from suitable study patients for
their participation in this sub-study.
Study procedure and time points
Research nurses will first conduct screening over the tele-
phone. If early checks of study eligibility are favourable,
study patients will be booked in for a face-to-face screen-
ing visit to further determine eligibility and explain what
is involved in the study. At the face-to-face visit, patients
will complete questionnaires, have a knee x-ray and MRI,
a blood test, and a clinical assessment by a study doctor to
ensure inclusion criteria are met. The study knee will be
defined as the one with symptomatic OA meeting all in-
clusion criteria.
Table 1 outlines the schedule of assessments. After
screening, there will be 4 study visits (month 0, 6, 12
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and 24). The same researcher nurses, who are blinded to
treatment allocation, will measure all clinical variables,
administer questionnaires, monitor compliance, and rec-
ord adverse events at these visits. Additional question-
naire mail outs will occur at months 3 and 18. Infusions
will occur at months 0 and 12; MRI scans will occur at
screening, month 6 and 24; knee x-ray will be performed
at screening; blood samples are taken at screening and
6 months, and urine samples are taken at baseline and
6 months. Three days following the infusion, patients
are contacted by phone interview to assess side effects of
acute phase reactions.
Quality assurance
To ensure high-quality execution of the trial in accord-
ance with the protocol, all trial staff will be trained by the
chief investigators and provided with a standard protocol
book (with details of standard operating procedures used,
trial contacts, visits, measurements, and monitoring) and
case report forms.
Outcome measures
Primary outcome measure: Absolute change in tibiofemoral
cartilage volume (mm3)
Knee MRI acquisition at the four study sites is presented
in Table 2, including details of sequences and parameters
being used. Tibial cartilage volume will be assessed on
the sagittal T1-weighted sequences by means of image
processing on an independent workstation using OsiriX
software (University of Geneva, Geneva, Switzerland).
The volumes of tibial cartilage plates (medial tibia and
lateral tibia) will be isolated from the total volume by
manually drawing disarticulation contours around the
cartilage boundaries on a section by section basis. These
data will then be re-sampled by means of bilinear and
cubic interpolation for final 3-D rendering. In our previ-
ous study, we demonstrated a coefficient of variation (CV)
Table 1 Schedule of assessments
Screening Baseline
(Month 0)
Day 3 Post-
Infusion
Month 3 Month 6 Month 12 Day 3 Post-
Infusion
Month 18 Month 24
Informed consent x
Clinical examination x
Knee x-ray x
Bloods x x*
Knee MRI x x x
Randomisation x
Clinic measures
Leg strength x x x x
Height and weight x x x
First void fasting urine x* x*
Infusion x x
Questionnaire measures
Demographics (sex, date of birth) x
Knee VAS x x x x x x x
Knee WOMAC x x x x x x
Medication use x x x x x x
Knee surgery x x x x x x
Knee joint injection x x x x
Safety (adverse events) x x x x x x x x
Acute phase reactions x x
Hand VAS x x x x x x
Back VAS x x x x x x
AQoL-4D x x x
Overall change in pain and function x
Treatment guessing x
*Only being performed at the Hobart, Melbourne and Sydney study sites
MRI magnetic resonance imaging, VAS visual analogue scale, WOMAC Western Ontario and McMasters Universities Osteoarthritis Index, AQoL-4D The Assessment
of Quality of Life
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of 2.1% for the medial tibia and 2.2% for the lateral tibia
[45], using this method.
Knee femoral cartilage volume will be determined on
the sagittal T1-weighted sequences by means of image
processing on an independent workstation using Carti-
scope™ (ArthroLab Inc., Montreal, Quebec, Canada), as
previously described [46–48]. The segmentation of the
cartilage-synovial interfaces will be carried out with the
semi-automatic method under reader supervision and
with corrections when needed. Cartilage volume will be
evaluated directly from a standardised view of 3D cartil-
age geometry as the sum of elementary volumes. In our
previous study, we demonstrated a CV of approximately
2% [46]. The cartilage volume assessment will be done
for the medial and lateral condyles delineated by the
Blumensaat’s line [48].
Tibiofemoral cartilage volume will be calculated as the
sum of both the tibial and femoral compartments at
screening and 24 months.
Secondary outcome measures
Improvement of knee pain at 3, 6, 12, 18, and
24 months Knee pain will be assessed using a 100 mm
VAS by asking “on this line, thinking about your right/
left knee, where would you rate your pain, using the last
7 days as a time frame”. We will also assess pain using
WOMAC [49], as we used this instrument to demon-
strate a clinically significant change in BML size
(140 mm2) [11]. Five items of WOMAC pain scale in
100-mm visual analog format [50] will be used to assess
pain during walking, using stairs, in bed, sitting or lying,
and standing during the last 7 days. Items will be
summed to create a total WOMAC pain score (range,
0–500). Incomplete items will be addressed according to
the WOMAC user guide [51]. The WOMAC pain score
will be considered invalid if there is more than one miss-
ing item. In the case there is only one missing item, the
remaining four items will be averaged and then multi-
plied by five.
Reduction in BML size over 6 and 24 months (mm2)
BMLs will be defined as an ill-defined hyperintensity in
the subchondral bone, on MRI. BMLs will be assessed on
the sagittal proton density weighted sequences at the med-
ial tibial, medial femoral, lateral tibial, lateral femoral and
patella sites by means of image processing on an inde-
pendent workstation using OsiriX software (University of
Table 2 Magnetic resonance imaging sequences and parameters at the four study sites
Machine and coil T1-weighted sagittal Proton density-weighted sagittal
Hobart (Note: used two different
MRI scanners. Patients had their
follow-up scans on the same
scanner in which they had their
screening scan).
1.5 T whole-body MR unit
(GE Optima 450 W, Milwaukee,
USA), using a dedicated 8-
channel knee coil
1.5 T whole-body MR unit (Siemens,
Espree), using a dedicated
15-channel knee coil
T1-weighted fat-saturated 3D
gradient-recalled acquisition; flip
angle 30 degrees; repetition time
38 msec; echo time 3 msec; field of
view 16 cm; 512 × 512 matrix; 1
excitation; slice
thickness 1.5 mm
T1-weighted fat-saturated 3D
gradient-recalled acquisition;
flip angle 30 degrees; repetition
time 31 msec; echo time 6.8 msec;
field of view 16 cm; 512 × 512 matrix;
1 excitation; slice
thickness 1.5 mm
Proton density fat-saturated 2D
fast spin echo sequence; flip angle
150 degrees; repetition time 3800
msec; echo time 35 msec; field of
view 16 cm; 512 × 512 matrix; 3
excitations;
slice thickness 3 mm
Proton density fat-saturated 2D
fast spin echo sequence; flip angle
150 degrees; repetition time 3830
msec; echo time 39 msec; field of
view 16 cm; 512 × 512 matrix; 3
excitations; slice thickness 3 mm
Melbourne 3.0 T whole-body MR unit (Philips,
Achieva, Medical Systems), using a
commercial 16-channel transmit receive
knee coil
T1-weighted fat-saturated 3D
gradient-recalled acquisition; flip
angle 15 degrees; repetition time
25.9 msec; echo time 9.2 msec; field
of view 16 cm; 320 × 320 matrix; slice
thickness 0.5 mm
Proton density fat-saturated 2D
fast spin echo sequence; flip angle
90 degrees; repetition time
3814 msec; echo time 25 msec;
field of view 16 cm; 720 × 720
matrix; slice thickness 2.5 mm
Sydney 1.5 T whole-body MR unit (Siemens,
Aera) using a dedicated 15-channel
transmit-receive knee coil
T1-weighted fat-saturated 3D
gradient-recalled acquisition; flip
angle 30 degrees, repetition time
31 msec; echo time 6.8 msec; field of
view 16 cm; 512 × 512 matrix; slice
thickness 1.5 mm
Proton density fat-saturated 2D
fast spin echo sequence; flip angle
150 degrees; repetition time
3830 msec; echo time 39 msec;
field of view 16 cm; 512 × 512
matrix; slice thickness 3 mm
Adelaide 1.5 T whole-body MR unit (Siemens,
Aera) using a dedicated 15-channel
transmit-receive knee coil
T1-weighted fat-saturated 3D
gradient-recalled acquisition; flip
angle 30 degrees, repetition time
14.7 msec; echo time 6.74 msec; field
of view 16 cm; 448 × 448 matrix; 1
excitation; slice thickness 1.5 mm
Proton density fat-saturated 2D
fast spin echo sequence; flip angle
180 degrees; repetition time
3200 msec; echo time 39 msec;
field of view 16 cm; 320 × 320
matrix; 1 excitation; slice thickness
3 mm
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Geneva, Geneva, Switzerland). The maximum size of each
lesion will be measured in mm2 using software cursors ap-
plied to the greatest area of the lesion, as previously de-
scribed in our pilot study [40]. Previously we have
demonstrated an intraclass correlation coefficient (ICC) of
0.97 [11], using this method. Total BML size (mm2) will
be calculated as the sum of every lesion within the medial
tibial, medial femoral, lateral tibial, lateral femoral and pa-
tella sites at screening, 6 and 24 months.
Other measurements
Knee function Knee function will be assessed using
WOMAC [49] at months 0, 3, 6, 12, 18 and 24. Seven-
teen items of the WOMAC function scale in 100-mm
visual analog format [50] will be used to assess function
during descending stairs, ascending stairs, rising from
sitting, standing, bending to floor/picking up an object,
walking on flat surface, getting in/out of the car, going
shopping, putting on socks/stockings, rising from bed,
taking off socks/stockings, lying in bed, getting in/out of
the bath, sitting, getting on/off the toilet, heavy domestic
duties, and light domestic duties during the last 7 days.
Items will be summed to create a total WOMAC func-
tion score (range, 0–1700). The WOMAC function score
will be considered invalid if there are more than 2 miss-
ing items. In the case there are two or less missing
items, the remaining items will be averaged and then
multiplied by 17 [51].
The assessment of quality of life (AQoL) Health
related quality of life and utility will be assessed using
The Assessment of Quality of Life (AQoL-4D) question-
naire [52] at 0, 6 and 24 months.
Co-pathology present on MRI Cartilage defects will be
assessed at the medial tibial, medial femoral, lateral tib-
ial, lateral femoral and patella sites as we have previously
described [53]: grade 0 = normal cartilage; grade 1 = focal
blistering and intracartilaginous low-signal intensity area
with an intact surface and base; grade 2 = irregularities
on the surface or base and loss of thickness < 50%; grade
3 = deep ulceration with loss of thickness > 50%; and
grade 4 = full-thickness chondral wear with exposure of
subchondral bone. In our previous study we demon-
strated the ICCs ranged from 0.80–0.95 [53] for the dif-
ferent knee sites, using this method.
Meniscal extrusion will be assessed as we have previ-
ously described [14] as the proportion of the menisci
affected by a partial or full extrusion (yes/no) at the
anterior, middle, and posterior horns (medially/laterally).
In our previous study we demonstrated the intra and
inter-reader ICC’s ranged from 0.85–0.92 for meniscal
extrusion [54].
Knee surgery and joint injections Whether the patient
underwent any knee surgery (including arthroscopies or
joint replacement surgery) during the trial, will be
assessed by questionnaire at screening, month 3, 6, 12,
18 and 24 months. Study patients will also give their
consent to have their data linked to the Australian
Orthopaedic Association National Joint Replacement
Registry (AOANJRR). Whether the patient had a joint
injection during the trial will be assessed at month 6, 12,
18 and 24 months.
Lower limb muscle strength Lower limb muscle
strength is a key correlate of pain and tends to increase
when pain is reduced [55]. We will assess leg strength
by dynamometry at the lower limb (involving both legs
simultaneously) at months 0, 6, 12 and 24. The muscles
measured in this technique are mainly the quadriceps
and hip flexors. The previously published repeatability
estimate (Cronbach’s α) for this method is 0.91 [45].
Overall change in pain and function At 24 months
patients will be asked to rate their overall change in pain
and function (compared to baseline) on this scale: Much
Worse, Moderately Worse, Slightly Worse, No Change,
Slightly Better, Moderately Better, and Much Better.
Anthropometry We will measure height (stadiometer),
weight (electric scales) and body mass index (BMI)
(weight/height2) at month 0, 6, and 24 months.
Radiographic knee OA A standing anteroposterior
semiflexed radiograph of the study knee will be per-
formed at screening. X-rays will be scored for joint space
narrowing on a four point scale (0–3) using the OARSI
atlas [43]. In our hands this method has very high repro-
ducibility with an ICC of 0.98 for joint space narrowing
and 0.99 for osteophytes [56].
Concomitant medication There are no restrictions with
regard to concomitant analgesic medications. Medica-
tion usage (including prescription, over-the-counter, and
natural/herbal remedies) will be documented at screen-
ing, month 3, 6, 12, 18 and 24 months. Patients will be
asked to keep medications as stable as possible but if
there are changes to the medications used or dose
changes during the trial the reason will be documented.
Blood samples Blood tests (Urea Electrolytes and
Creatinine (UEC), calcium and vitamin D assays) will
occur for safety at screening to assess inclusion criteria.
Storage of blood samples will occur at screening and
6 months for future testing at the following study sites:
Hobart, Melbourne, and Sydney. The blood will be stored
at − 80 °C.
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Urine samples Storage of first void fasting urine sam-
ples will occur at month 0 and 6 for future testing at the
following study sites: Hobart, Melbourne, and Sydney.
The urine will be stored at − 80 °C.
Treatment guessing At 24 months patients will be
asked what treatment they think they received with the
following options: zoledronic acid (active treatment),
placebo, or not sure.
Other site pain Hand pain and low back pain will be
assessed at months 0, 3, 6, 12, 18 and 24 using a
100 mm VAS by asking “on this line, thinking about
your most painful hand/low back, where would you rate
your pain, using the last 30 days as a time frame”.
Safety assessment
Adverse events will be monitored throughout the study.
Standard safety and efficacy monitoring will be per-
formed through regular face-to-face visits and phone
calls between visits. The patients are requested to report
any adverse events to the research staff spontaneously.
Details of the adverse event and its relationship with
study intervention will be recorded and reported to the
Ethics Committees.
Patients will be phoned 3 days following their infusion
in order to determine if they have experienced any
symptoms of acute phase reactions, including flushing,
fever, joint pains, and muscle aches.
Sample size calculations
Primary outcome
In our pilot study [40] we found that zoledronic acid sig-
nificantly reduced the size of BMLs over 6 months com-
pared to placebo. Therefore our sample size calculations
for this trial were modelled based on the assumption
that a decrease in BML size will translate to a reduction
in cartilage volume loss over time. This assumption is
valid based on the unequivocal evidence from observa-
tion data demonstrating that BMLs predict cartilage vol-
ume loss over time [14–17, 38, 54, 57–59].
The changes in BML area seen in our pilot study were
− 198.6 mm2 (zoledronic acid treatment) and − 22.8 mm2
(placebo) with regression root mean square error of
261.5 mm2 (i.e. standard deviation (SD)) [40], at 6 months.
Unpublished observational data from our Tasmanian
Older Adult Cohort (TASOAC) study allowed us to model
the effect a decrease in BML size would have on tibiofe-
moral cartilage volume loss over 24 months. Using
follow-up data for 120 TASOAC participants with BMLs,
we used linear regression to estimate the relationship be-
tween absolute change in tibiofemoral cartilage volume
and final BML area with adjustment for age, sex, BMI and
length of follow-up. The results can be used to predict
each subject’s two-year change in tibiofemoral cartilage
volume from their final BML area, and the change when
final BML area is reduced by 198.6 mm2 (expected under
treatment) or 22.8 mm2 (expected under placebo). To take
account of individual variation, the calculations were
repeated in 1000 replications with the exact changes in
final BML area replaced by random values of 198.6 mm2
(treatment) firstly and 22.8 mm2 (placebo) secondly, and
with SD 261.5 mm2 in each case. The resulting estimates
of tibiofemoral cartilage loss, which are expected from the
6 month changes in BML area, were − 824.0 mm3 (SD
273.0) in the treatment group and − 928.3 mm3 (SD 272.3)
in the placebo group. With this difference, 132 patients
(allowing for 20% drop out over 24 months) recruited to
each arm of the trial will provide 80% power with 5%
probability of type I error (alpha = 0.05). This estimate is
conservatively based on 6-month change in BML area for
n = 59 patients in our pilot study [40] and assumes no
further improvement in BMLs after this time (although
they may continue to reduce with zoledronic acid over
24 months).
Secondary outcome
For our secondary outcomes (improvement in pain and
reduction in BML size) a sample size of 132 patients in
each arm will provide 98.9 and 99.6% power to detect
the adjusted treatment differences in knee pain scores
and BML area respectively that were observed in our
pilot study [40].
Statistical analysis
The primary analyses will be intention-to-treat analyses
of primary and secondary outcomes. Per protocol ana-
lyses will be performed as the secondary analyses.
Changes in absolute tibiofemoral cartilage volume,
knee pain and BML size will be analysed using a linear
mixed model with treatment, month and their inter-
action (treatment × month) as covariates. The correl-
ation within trial centres and the repeated measures will
be addressed using trial centre and patient identification
as random intercepts. Month will be treated as random
effect to allow different treatment effects among patients
over time. Change in outcome measures within each
group and difference of the changes between groups
from baseline to follow-up will be calculated using linear
combinations of the estimated coefficients. If there are
baseline imbalances between treatment groups, we will
consider adjusting for them based on whether we regard
the imbalance as clinically significant. Missing data
caused by loss to follow-up and nonresponses will be ad-
dressed by adding baseline complete variables that can
explain the missingness to the regression models.
Secondary analysis for missing data will be performed
using multiple imputation by chained equations. Baseline
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variables with complete data will be used for data imput-
ation assuming missing at random.
Pre-specified stratified analyses will be performed to
examine which subgroups may respond better to treatment.
Potential stratification variables include radiographic knee
OA and co-pathology present on MRI. Statistical signifi-
cance will be set as a two-sided P value < 0.05.
Data integrity and management
All collected data are recorded using case report forms
which will be processed centrally at the Menzies Institute
for Medical Research, University of Tasmania. The hard
copies of the case report forms will be stored in a locked
area at each study site with secured and restricted access.
The electronic data will be stored on password protected
servers with restricted access. All data collected will be
kept strictly confidential. Daily back ups of all electronic
data will occur to minimise any risk of lost data. Data
transfer will be encrypted with all data de-identified. Only
members of the research team who need to contact study
patients, enter data or perform data quality control will
have access to patient information.
After study completion, paper copies of data will be ar-
chived in secure storage. Identifiers will not be removed,
in case follow-up of study patients is necessary; however,
electronic data will continue to be kept in a secure elec-
tronic database. This will remain password protected
and with access given only to the study investigators un-
less otherwise authorised by the study team.
Withdrawal
If patients withdraw from the study before 24 months of
follow-up, the reason and date will be recorded. Patients
who withdraw after a minimum of 9 months will be re-
quested to have a third MRI scan on their study knee.
Roles and responsibilities and monitoring
The University of Tasmania (as the trial sponsor) and
the principal investigators are responsible for all aspects
of the trial, including design, conduct and oversight. The
principal investigators will monitor the conduct and
progress of the project at each site. The trial coordinator
will visit each study site to make sure that all trial proce-
dures are compliant with the trial protocol. The princi-
pal investigators and the research team will have regular
teleconferences to ensure efficient study execution and
ongoing monitoring of the study progress, with sum-
mary documents circulated after each meeting. A Data
and Safety Monitoring Board was not convened for this
trial as zoledronic acid is approved in Australia by the
Therapeutic Goods Administration (TGA) and has a
well-known safety profile. The trial is also being moni-
tored at each site by a practicing rheumatologist with ex-
perience prescribing zoledronic acid.
Dissemination plans
The results of this study will be presented at conferences
and published in scientific journals. Any notes or publi-
cations arising from our research will be de-identified.
Only aggregate statistical results will be presented.
The outcomes of the project will be disseminated to
study patients using non-technical language. The scien-
tific paper will be available for dissemination to patients’
should they wish to receive it, after the manuscript has
been accepted for publication. Dissemination of the
overall study findings to the patients will occur in a
de-identified manner and be based on the entire study
population.
Discussion
We proposed a multicentre, randomised, double blind
placebo controlled trial to determine whether annual
infusions of zoledronic acid reduces the rate of knee car-
tilage volume loss, improves knee pain and reduces
BML size, compared to placebo in people with clinical
knee OA, significant knee pain and subchondral BMLs.
If zoledronic acid proves effective, it will offer a novel
therapeutic approach to reduce knee OA progression.
Zoledronic acid is an established treatment for osteo-
porosis [28, 60]. Bisphosphonates have effects through a
variety of mechanisms, including effects on the subchon-
dral bone and osteochondral junction [6]. Bisphospho-
nates may also have anti-inflammatory actions [61, 62];
which may play a role in an immediate analgesic benefit,
as distinct from that which might arise as a consequence
of osteochondral structural alteration, and thus may
explain why analgesic benefits may not persist beyond the
period of drug use. Overall, the mechanism and direction
of effect remains controversial, the evidence suggests that
bisphosphonates have effects on the subchondral bone.
Radiographs are a tool commonly used to assess disease
progression in OA, but it is not the optimal method. It is
moderately responsive to change in terms of standardised
response means (SRM) [63]; however, it is insensitive to
change in cartilage measures [64]. MRI offers a much
better assessment, and OA features on MRI are better
targeted for defining and following disease progression.
Using MRI, cartilage volume/thickness loss predict knee
replacement [18, 65–67] and have similar levels of
sensitivity to discriminate treatments in clinical trials [38].
Accordingly, MRI assessment of cartilage morphology is
now recommended for the evaluation of disease progres-
sion as an endpoint for clinical trials [66, 68]. Simultan-
eously, we will assess change in knee pain over time using
a 100 mm VAS, and WOMAC [49] as secondary end-
points. Thus, the findings from this study will show
whether zoledronic acid treatment has both symptom
modifying and disease modifying effects.
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Zoledronic acid is associated a suite of well charac-
terised acute phase reactions [44]. While these reactions
are of mild-moderate intensity, and self-limiting in
duration, they are common (incidence ~ 30%) and un-
pleasant. We included a sub-study to investigate the effi-
cacy of adding 10 mg methylprednisolone immediately
following the zoledronic acid infusion. Methylpredniso-
lone, an anti-inflammatory drug, might reduce rates of
acute phase reactions by reducing inflammation due to
the zoledronic acid infusion, as intermediates in the
mevalonate pathway activated by blocking farnesyl
pyrophosphate synthase (isopentenyl diphosphate and
dimethylallyl diphosphate) accumulate in monocytes
when the enzyme is blocked and result in activation of
adjacent γδT cells, with the release of interferon-δ and
TNF [69]. We hypothesised that administration of meth-
ylprednisolone after zoledronic acid infusion will reduce
rates of acute phase reactions.
Conclusion
In summary, knee OA is a major but poorly understood
public health problem. Our novel preliminary data showed
that zoledronic acid improved knee pain and reduced the
size on BMLs in OA patients [40]. If zoledronic acid can
reduce knee pain, size of BMLs, and slow cartilage loss, it
suggests great potential for cost savings through a delay or
reduced need for joint replacement surgery, and potential
for great improvements in quality of life for OA suffers.
The success of this study will provide scientific evidence
for using a cost-effective and innovative approach to ad-
dressing this clinically significant problem and lends itself
to incorporation in routine clinical practice.
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